That sounds like the setup to a late-night philosophy seminar, but ovarian cancer has apparently been workshopping the question in secret. This new paper lands on a very practical, very unsettling answer: sometimes the tumor does not become smarter in some grand supervillain way - it just hires...
Cancer treatment sometimes feels like logistics with better microscopes. You fix a supply-chain failure, reroute the trucks, and for a while everything runs on schedule - then the warehouse starts quietly swapping labels, opening side doors, and inventing a whole new inventory system just to spite...
Hormone receptor-positive breast cancer often responds to endocrine therapy at first, which is lovely in the way umbrellas are lovely until the hurricane arrives. Over time, many tumors learn new tricks and stop listening. One accomplice is HER3, a cell-surface receptor that shows up in a lot of...
For years, the standard story in adult Ph+ ALL went something like this: get the leukemia into remission, then hustle the patient toward an allogeneic stem cell transplant. That transplant brings in donor immune cells that can attack leftover leukemia - a useful trick called the...
Good parenting means you do not let the rowdy kid in the grocery store set aisle nine on fire, and your body runs a similar policy with cells every day. Most of the time it works: damaged cells get corrected, removed, or sternly escorted off the premises. Glioblastoma, unfortunately, is what...
Glucocorticoids are stress hormones. Think cortisol, dexamethasone, that whole family. They bind the glucocorticoid receptor, which then heads into the nucleus and starts flipping genetic switches like a tired office manager with too much authority and not enough supervision [6,7]. In cancer, that...
To follow the paper, you only need one bit of metabolism. Cells use the pentose phosphate pathway, or PPP, to make NADPH, which is basically biochemical emergency cash. NADPH helps cells neutralize reactive oxygen species, the nasty molecules that pile up during stress. If chemotherapy is a house...
My grandmother would call this "trying to tell who's in trouble before the trouble shows up." That is basically what this new cancer AI paper is doing, except instead of tea leaves it uses pathology slides, genomic data, and enough cross-attention machinery to make a trial statistician reach for...
The 1962 Alcatraz escape remains one of America's most stubborn unsolved mysteries - three inmates vanished from a prison everyone swore was inescapable, and six decades later, nobody can say for certain how they pulled it off. A research team led by scientists at MD Anderson Cancer Center just...
This paper looks at a brutal corner of blood cancer care: adults with acute myeloid leukemia, or AML, whose disease either never really responded or came roaring back after initial treatment. That situation is called relapsed or refractory AML, which is doctor-speak for "the first counter-offensive...
If you reheated leftovers today instead of cooking a whole new meal, congratulations, you already understand the basic logic behind maintenance therapy. In cancer care, the idea is similar: after the big first round of treatment does its thing, maybe you do not stop completely. Maybe you keep a...
RNA polymerase II is the enzyme that reads DNA and makes messenger RNA. That sounds tidy until you remember it is doing this on crowded chromatin, while DNA replication and repair are happening nearby, all inside a nucleus that has the traffic design of a medieval alleyway. When Pol II stalls,...
HER2-low breast cancer is defined by not having quite enough HER2 to be a big deal, and yet here we are, finding out it may hide some very big deals. Oncology does love a contradiction. It keeps the lights on.
That, in a sentence, is why this new DLBCL paper is interesting. The researchers used single-cell data plus machine learning to hunt for the molecular equivalent of the ringleader in a very bad group chat, and they landed on a three-part axis: IRF4, PAICS, and LDHA. If those names sound like a...
[Stage direction: A single B-cell stands center stage under a flickering spotlight. It clutches a chromosome 11 fragment that clearly belongs somewhere else. The cell cycle clock on the wall spins too fast. Enter, stage left, an increasingly sophisticated lineup of molecular inhibitors, engineered...
Classified ad: Wanted - one punctual extracellular vesicle, size roughly "smaller than your patience on hold with insurance," must report to a designated nanowell, carry useful molecular gossip, and stop smearing fluorescence all over the place.
Some tumors do not grow like a lone trumpet blaring off-key. They conduct a whole unruly orchestra - rewriting the score, bribing the percussion section, and somehow convincing the security staff to nap in the lobby.
Here's the thing about a garden gone to seed - you can't fix it by just looking at the soil. You need to check the roots, the water table, what's pollinating what, and whether that vine creeping across the fence is actually strangling your tomatoes. Cancer works the same way. For decades,...
The problem with cancer immunotherapy is that your T cells can show up to the tumor and still behave like interns on their first day - badge clipped on, eyes wide, not entirely sure which button starts the machinery.
The bone marrow biopsy - beloved by exactly zero patients and tolerated by millions - has enjoyed an unchallenged reign over leukemia monitoring for decades. It is survived by its successors: a tube of blood, 96 molecular targets, and a research team at Johns Hopkins who just made its monopoly look...